Search Results for: covid-19
Articles
Valneva & Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate February 7, 2022
Valneva SE and Pfizer Inc. recently reported further positive Phase 2 data for their Lyme disease vaccine candidate, VLA15. Based on these new results….
Pardes Biosciences Announces FDA Clearance of IND Application for Oral Antiviral Drug Candidate for the Treatment & Prevention of SARS-CoV-2 Infections February 3, 2022
Pardes Biosciences, Inc. recently announced its Investigational New Drug (IND) application for PBI-0451 has been cleared by the US FDA....Arch Scientists Publish Data on the Mechanism of Action & Efficacy of Lead Drug Candidate LSALT Peptide in the Prevention of Acute Kidney Injury February 3, 2022
Arch Biopartners Inc. recently announced a scientific team led by Dr. Daniel Muruve at the University of Calgary, and their...Veru Enters Clinical Trial Collaboration & Supply Agreement With Eli Lilly & Company February 1, 2022
Veru Inc. recently announced it has entered into a clinical trial collaboration and supply agreement with Eli Lilly and Company. The objective of the collaboration is to evaluate the efficacy and safety of….
Celsion Corporation Advances Proof of Concept to Non-human Primate Challenge Study Against SARS-CoV-2 With In-Process Vaccine Candidate January 31, 2022
Celsion Corporation recently announced it has engaged BIOQUAL, Inc., a preclinical testing contract research organization, to conduct a non-human primate (NHP) challenge study with Celsion’s DNA-based approach for….
Yamo Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study of L1-79 in Autism Spectrum Disorder January 27, 2022
Yamo Pharmaceuticals recently announced the first patient has been treated in a Phase 2 study of L1-79 in adolescents and...PDS Biotech Announces Preclinical Data for PDS0202 Universal Influenza Vaccine January 27, 2022
PDS Biotechnology Corporation recently announced preclinical data for its universal flu vaccine, which was shown to be effective against….
BetterLife Receives FDA Response On Its Pre-IND Application For Major Depressive Disorder (MDD) Treatment With BETR-001 January 20, 2022
BetterLife Pharma Inc. recently announced it has received a written response from the US FDA to its pre-investigational new drug...BetterLife Obtains Positive In Vivo Oral Bioavailability, Food Effect & Pharmacokinetics Data for BETR-001 January 18, 2022
BetterLife Pharma Inc. recently announced it has obtained positive results from an in vivo oral bioavailability and food-effect pharmacokinetic (PK)...SPECIAL FEATURE - Analytical Testing Trends in 2022 January 17, 2022
Contributor Cindy H. Dubin reports on the innovative technologies and techniques that several leading outsourcing providers currently offer for both small and large molecules.
FORMULATION FORUM - Formulation & Process of Lipid Nanoparticles for Delivery of Small Molecules & Biologicals January 17, 2022
Jim Huang, PhD, explains how recently, lipid nanoparticles have emerged as a drug delivery system for biologicals, especially for the COVID-19 mRNA vaccines in which LNPs play a vital role in transporting mRNA into the target cells.
ORGAN-ON-A-CHIP - A Novel Way to Accurately Test Delivery of Non-Standard Formulations January 17, 2022
David Hughes, PhD, says ultimately, the goal of OOC technology is to improve the translatability of data between the lab and the clinic. Through a lung-on-a-chip approach, it is possible to recreate the histoarchitecture, phenotype, and function of bronchial and alveolar areas of the lung.
EXOSOMES - The Next Evolution in Therapy Delivery Beyond the Cell Membrane: The Promise of Exosomes January 17, 2022
Linda Marbán, PhD, says perhaps the best way to get past the cell membrane is to deliver contents the same way that cells send information to each other. And that is by the exosome, which in the case of targeted therapy delivery, has been identified as an alternative that shows powerful promise.
Clinical Trial Begins in the UK to Investigate 3-in-1 High Blood Pressure Pill January 17, 2022
George Medicines recently announced its proprietary triple low-dose combination pill, GMRx2, will be trialed in UK patients with high blood...EXECUTIVE INTERVIEW - GATC Health & Liquid Biosciences: Faster, Cheaper, More Effective Drug Discovery January 14, 2022
Ian Jenkins, Director of Science, and Jeff Moses, CMO at GATC Health, discuss the combined benefits of their MAT platform and Liquid Biosciences’ Emerge mathematical evolution platform to help identify the right biology sooner and focus on a smaller set of potential compounds early in the pre-clinical development process to enable pharma companies to develop drugs with more efficiency and a higher success rate.
Proscia & Datavant Partner to Connect Pathology Data With Health Data Ecosystem for Life Sciences R&D January 13, 2022
Proscia and Datavant recently announced a partnership that will provide life sciences companies with digitized pathology data to power the development...Q-VANT Biosciences Launches to Solve the Pharmaceutical Industry Problem of Limited Quillaja Saponin-Based Adjuvants for Life-Saving Vaccines January 12, 2022
Q-VANT Biosciences has launched as the first company to achieve a 100% sustainable way to meet the growing global vaccine market demand for Quillaja saponin-based adjuvants including QS-21. QS-21 is considered the “Gold Standard” adjuvant for enhancing immune….
COVAXIN (BBV152) Booster Shown to Neutralize Both Omicron & Delta Variants of SARS-CoV-2 January 12, 2022
Ocugen, Inc.and its partner, Bharat Biotech recently announced results from a study conducted at Emory University demonstrating that sera from subjects who received a booster dose of candidate vaccine….
Definitive Agreement to Acquire Exelead Will Strengthen the CDMO Offering for mRNA of the Life Science Business of Merck KGaA, Darmstadt, Germany January 11, 2022
Merck KGaA, Darmstadt, Germany recently announced the signing of a definitive agreement to acquire Exelead, a biopharmaceutical contract development and...Veru Announces FDA Grant of Fast Track Designation for Enobosarm for the Treatment of AR+ ER+ HER2- Metastatic Breast Cancer January 10, 2022
Veru Inc. recently announced the US FDA has granted Fast Track designation to the Phase 3 registration program for the investigation of enobosarm, a selective androgen receptor targeting agonist, for the treatment of….
